By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Synthetic peptidomimetic / dipeptide-derived small molecule
Entity type
Small molecule
Research focus
Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic
Human evidence
Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified.
Regulatory status
FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally.
Main limitations
Robust efficacy in healthy adults, long-term safety or a modern validated nootropic treatment regimen.
Safety
No large contemporary healthy-volunteer safety programme was identified; evidence gaps should be prominent.
Evidence reviewed
2026-09-18
i
Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
No large contemporary healthy-volunteer safety programme was identified; evidence gaps should be prominent.
Modern large randomized safety datasets are lacking. 'Widely used' or long market presence in some regions should not be mistaken for robust contemporary safety evidence.
Technical details
Mechanism / biologyMechanistic hypotheses include modulation of neurotrophin signalling, excitatory neurotransmission and oxidative/inflammatory pathways, but translation to human cognitive enhancement is uncertain.
Route / formulation boundaryMost clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols.
Identity / data-quality noteCorrectly classify as omberacetam/peptidomimetic rather than a conventional peptide.
Study / label regimen evidenceLimited human regimen identified. A 60-patient open prospective post-stroke study reported 20 mg/day for two months; this is not a healthy-person dosing recommendation.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
2outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
